95 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
.
Overview
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients … Therapeutics Holdings, Inc., Equilibre Biopharmaceuticals Corp., Johnson & Johnson Innovative Medicine, Neuro3 Therapeutics, Inc., Praxis Precision
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
is a part.
Overview
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients … products in development from Biohaven Ltd., Cerevel Therapeutics Holdings, Inc., Equilibre Biopharmaceuticals Corp., Johnson & Johnson Innovative Medicine
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
27 Nov 23
Other Events
7:03am
.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative
8-K
EX-99.1
xnr3en5n9 l9fv8r0o
9 Nov 23
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
4:06pm
8-K
EX-99.1
dzcogxe
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
exgyj1n1
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
dedj cpez
8 Aug 23
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
4:07pm
8-K
EX-99.1
52a5rn4o
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
sgj pw67dnxuyxs
8 Nov 22
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
5qxxvkekuz6o6pk79
7 Nov 22
Other Events
4:06pm
424B5
09phiyi3mzgj
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
bnoy1j56282m5z
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
vhw0l5
21 Jun 22
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
7:03am